Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery
- 30 January 2025
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 31 (4) , 388-398
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (KL2, KL2TR002381, UL1TR002378, R25GM143298)
- Children's Tumor Foundation (2022-04-007)
- National Institute of General Medical Sciences
- Georgia Clinical and Translational Science Alliance (UL1TR002378, KL2TR002381)
This publication has 80 references indexed in Scilit:
- Neurofibromatosis type 1: New developments in genetics and treatmentJournal of the American Academy of Dermatology, 2021
- Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with SelumetinibCurrent Oncology Reports, 2021
- Adeno-associated virus (AAV) vectors: Rational design strategies for capsid engineeringCurrent Opinion in Biomedical Engineering, 2018
- Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848The American Journal of Human Genetics, 2018
- Adeno-Associated Virus (AAV) as a Vector for Gene TherapyBioDrugs, 2017
- In vivo tissue-tropism of adeno-associated viral vectorsCurrent Opinion in Virology, 2016
- Systemic delivery of adeno-associated viral vectorsCurrent Opinion in Virology, 2016
- In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy VectorCell Reports, 2015
- Gene Therapy for Heart Failure: Where Do We Stand?Current Cardiology Reports, 2013
- Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOHHuman Mutation, 2010